

ASTRAZENECA PLC  
Form 6-K  
May 01, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of May 2019

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82-\_\_\_\_\_

AstraZeneca PLC

## INDEX TO EXHIBITS

1.  
Director/PDMR Shareholding

1 May 2019 12:00 BST

### Transactions by Persons Discharging Managerial Responsibilities Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 29 and 30 April 2019, it was notified of transactions in the Company's ordinary shares of \$0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) as set out below. Two ADSs are equivalent to one Ordinary Share.

| PDMR            | Position                | Nature of the transaction   | Quantity | Price       |
|-----------------|-------------------------|-----------------------------|----------|-------------|
| Pascal Soriot   | Chief Executive Officer | Purchase of Ordinary Shares | 17,100   | GB£58.255   |
| Philip Broadley | Non-Executive Director  | Purchase of Ordinary Shares | 520      | GB£57.38    |
| Sheri McCoy     | Non-Executive Director  | Purchase of ADSs            | 2,372    | US\$38.1783 |
| Sheri McCoy     | Non-Executive Director  | Purchase of ADSs            | 100      | US\$38.172  |
| Deborah DiSanzo | Non-Executive Director  | Purchase of ADSs            | 1,000    | US\$38.3056 |

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name  
Pascal Soriot

2 Reason for the notification

a) Position/status  
Chief Executive Officer

b) Initial notification /Amendment  
Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: ASTRAZENECA PLC - Form 6-K

- a) Name AstraZeneca PLC
- b) LEI PY6ZZQWO2IZFZC3IOL08

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

- Description of the financial instrument, type of instrument Ordinary Shares of US\$0.25 each in AstraZeneca PLC
- a) Identification code GB0009895292
- b) Nature of the transaction Share purchase
- c) Price(s) and volume(s)
- | Price(s)  | Volume(s) |
|-----------|-----------|
| GB£58.255 | 17,100    |

Aggregated information

- d) - Aggregated volume Not applicable - single transaction

- Price

- e) Date of the transaction 29 April 2019

- f) Place of the transaction XLON

1 Details of the person discharging managerial responsibilities / person closely associated

- a) Name Philip Broadley

2 Reason for the notification

- a) Position/status Non-Executive Director

- b) Initial notification /Amendment Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

AstraZeneca PLC

b) LEI

PY6ZZQWO2IZFZC3IOL08

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument Identification code

Ordinary Shares of US\$0.25 each in AstraZeneca PLC

GB0009895292

b) Nature of the transaction

Share purchase

c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|----------|-----------|
| GB£57.38 | 520       |

Aggregated information

d) - Aggregated volume

Not applicable - single transaction

- Price

e) Date of the transaction

30 April 2019

f) Place of the transaction

XLON

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name

Sheri McCoy

2 Reason for the notification

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|    |   |  |           |
|----|---|--|-----------|
| a) | Position/status   | Non-Executive Director                                 |           |
| b) | Initial notification /Amendment   | Initial notification                                   |           |
| 3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor   |  |           |
| a) | Name  | AstraZeneca PLC  |           |
| b) | LEI   | PY6ZZQWO2IZFZC3IOL08                                   |           |
| 4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |  |           |
|    | Description of the financial instrument, type of instrument   | AstraZeneca PLC American Depositary Shares             |           |
| a) | Identification code   | CUSIP: 046353108                                       |           |
| b) | Nature of the transaction   | Purchase of AstraZeneca PLC American Depositary Shares |           |
| c) | Price(s) and volume(s)  | Price(s)   | Volume(s) |
|    |   | US\$38.1783  | 2,372     |
|    |   | US\$38.175   | 100       |
|    | Aggregated information  |  |           |
| d) | - Aggregated volume   | 2,472  |           |
|    | - Price   | US\$38.178   |           |
| e) | Date of the transaction   | 29 April 2019  |           |
| f) | Place of the transaction  | NYSE   |           |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

1 Details of the person discharging managerial responsibilities / person closely associated

a) Name  
Deborah DiSanzo

2 Reason for the notification

a) Position/status  
Non-Executive Director

b) Initial notification /Amendment  
Initial notification

3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name  
AstraZeneca PLC

b) LEI  
PY6ZZQWO2IZFZC3IOL08

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument  
a) Identification code  
AstraZeneca PLC American Depositary Shares

CUSIP: 046353108

b) Nature of the transaction  
Purchase of AstraZeneca PLC American Depositary Shares

c) Price(s) and volume(s)  
Price(s) Volume(s)  
US\$38.3056 1,000

Aggregated information

d) - Aggregated volume  
Not applicable - single transaction

- Price

e) Date of the transaction  
29 April 2019

f) Place of the transaction

NYSE

#### About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit [astrazeneca.com](http://astrazeneca.com) and follow us on Twitter @AstraZeneca.

#### Media Relations

|                         |           |                  |
|-------------------------|-----------|------------------|
| Gonzalo Viña            | UK/Global | +44 203 749 5916 |
| Rob Skelding            | UK/Global | +44 203 749 5821 |
| Matt Kent               | UK/Global | +44 203 749 5906 |
| Jennifer Hursit         | UK/Global | +44 203 749 5762 |
| Christina M Hägerstrand | Sweden    | +46 8 552 53 106 |
| Michele Meixell         | US        | +1 302 885 2677  |

#### Investor Relations

|                     |  |                  |
|---------------------|--|------------------|
| Thomas Kudsk Larsen |  | +44 203 749 5712 |
| Henry Wheeler       | Oncology                               | +44 203 749 5797 |
| Christer Gruvris    | BioPharma - Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick Stone          | BioPharma - Respiratory; Renal         | +44 203 749 5716 |
| Josie Afolabi       | Other                                  | +44 203 749 5631 |
| Craig Marks         | Finance; Fixed Income                  | +44 7881 615 764 |
| Jennifer Kretzmann  | Retail Investors; Corporate Access     | +44 203 749 5824 |
| US toll-free        |  | +1 866 381 72 77 |

Adrian Kemp  
Company Secretary  
AstraZeneca PLC

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 May 2019

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary

